Christopher Sinz
Overview
Explore the profile of Christopher Sinz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blume S, Garg A, Marti-Mateos Y, Midha A, Chew B, Lin B, et al.
Cell
. 2025 Feb;
PMID: 39965572
We have previously demonstrated that chronic inhaled hypoxia is remarkably therapeutic in the premier animal model of mitochondrial Leigh syndrome, the Ndufs4 knockout (KO) mouse. Subsequent work has extended this...
2.
Ullman J, Mellem K, Xi Y, Ramanan V, Merritt H, Choy R, et al.
Sci Transl Med
. 2024 Jan;
16(730):eadf1691.
PMID: 38232139
Glycogen synthase 1 (GYS1), the rate-limiting enzyme in muscle glycogen synthesis, plays a central role in energy homeostasis and has been proposed as a therapeutic target in multiple glycogen storage...
3.
Robinson G, Zielstorff M, Sevilla R, Vanko A, Sinz C, Cicmil M, et al.
Mol Imaging Biol
. 2023 Dec;
26(1):188.
PMID: 38129621
No abstract available.
4.
Robinson G, Zielstorff M, Sevilla R, Vanko A, Sinz C, Cicmil M, et al.
Mol Imaging Biol
. 2023 Dec;
26(1):179-187.
PMID: 38057646
Purpose: Hypoxia-inducible factor (HIF) drives transcription of critical hypoxia response genes, increasing the production of red blood cells in low oxygen conditions. In the absence of hypoxia, HIF is degraded...
5.
Morriello G, Dwyer M, Chen Y, Ginetti A, Xu S, Lu J, et al.
Bioorg Med Chem Lett
. 2021 May;
44:128082.
PMID: 33991626
A focused SAR study was conducted on a series of N1-substituted pyrazolopyrimidinone PDE2 inhibitors to reveal compounds with excellent potency and selectivity. The series was derived from previously identified internal...
6.
Wilson J, Kurukulasuriya R, Sinz C, Lombardo M, Bender K, Parker D, et al.
Bioorg Med Chem Lett
. 2016 Jun;
26(12):2947-2951.
PMID: 27240550
A novel series of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists are described. The series was designed to address the suboptimal PK (pharmacokinetic) and off-target profile of a class of N-aryl-benzo-[1,4]-oxazepine-4-carboxamides, represented by 1,...
7.
Oh D, Walenta E, Akiyama T, Lagakos W, Lackey D, Pessentheiner A, et al.
Nat Med
. 2014 Jul;
20(8):942-7.
PMID: 24997608
It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals,...
8.
Sinz C, Bittner A, Brady E, Candelore M, Dallas-Yang Q, Ding V, et al.
Bioorg Med Chem Lett
. 2011 Oct;
21(23):7124-30.
PMID: 22030028
A novel class of N-aryl-2-acylindole human glucagon receptor (hGCGR) antagonists is reported. These compounds demonstrate good pharmacokinetic profiles in multiple preclinical species. One compound from this series, indole 33, is...
9.
Sinz C, Chang J, Lins A, Brady E, Candelore M, Dallas-Yang Q, et al.
Bioorg Med Chem Lett
. 2011 Oct;
21(23):7131-6.
PMID: 22001094
In the course of the development of an aminobenzimidazole class of human glucagon receptor (hGCGR) antagonists, a novel class of cyclic guanidine hGCGR antagonists was discovered. Rapid N-dealkylation resulted in...